Results 211 to 220 of about 482,975 (382)

MANAGEMENT OF TOOTH EXTRACTIONS IN PATIENTS RECEIVING THE NEW ORAL ANTICOAGULANTS

open access: diamond, 2022
Lyudmila Vladimirova‐Kitova   +3 more
openalex   +1 more source

CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence for regulatory science and innovation in pharmacogenomics (CERSI‐PGx)

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Clopidogrel, an antiplatelet agent, is currently licensed in the United Kingdom for the prevention and treatment of atherothrombotic events in cerebrovascular disease, coronary artery disease and peripheral arterial disease. Clopidogrel requires metabolic activation by the cytochrome P450 enzyme CYP2C19 to be effective.
Cinzia Dello Russo   +22 more
wiley   +1 more source

Anticoagulation therapy for intra-abdominal hypertension in patients with acute pancreatitis. [PDF]

open access: yesBMC Gastroenterol
Ge Y   +9 more
europepmc   +1 more source

Comparative effectiveness and safety of oral anticoagulants in patients with atrial fibrillation using antiarrhythmic drugs: An international cohort study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Our international cohort study assessed the comparative effectiveness and safety of direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs) among patients with non‐valvular atrial fibrillation (NVAF) using antiarrhythmic drugs. Methods Using the United Kingdom's (UK's) Clinical Practice Research Datalink Aurum and Québec claims data, we
Fabian Maximilian Meinert   +5 more
wiley   +1 more source

Editorial: Venous thromboembolism and pregnancy

open access: yesFrontiers in Cardiovascular Medicine, 2022
Bernard Tardy, Laurent Bertoletti
doaj   +1 more source

Home - About - Disclaimer - Privacy